USPTO Patent Grant: Chemokine CXCR4 Receptor Modulators

ChangeBridge: Patent Grants - Organic Chemistry (C07D)

Published March 24th, 2026

Detected March 24th, 2026

Summary

The USPTO has granted a patent to Emory University for chemokine CXCR4 receptor modulators and their uses. The patent covers compounds and pharmaceutical compositions that can be used for managing various conditions including viral infections, abnormal cellular proliferation, and cancer.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has granted patent US12582645B2 to Emory University, covering novel chemokine CXCR4 receptor modulators and their therapeutic applications. The patent details compounds, pharmaceutical compositions, and methods for managing conditions such as viral infections, abnormal cellular proliferation, retinal degeneration, inflammatory diseases, and cancer. It also outlines potential co-administration with other active ingredients like antiviral agents or chemotherapeutic agents.

This patent grant signifies the protection of intellectual property related to specific pharmaceutical compounds and their uses. While not imposing direct regulatory obligations on other entities, it establishes exclusive rights for the assignee, potentially impacting future research, development, and commercialization efforts in this therapeutic area. Companies operating in the pharmaceutical and biotechnology sectors, particularly those involved in CXCR4-related research or treatments, should be aware of this granted patent and its scope.

Source document (simplified)

← USPTO Patent Grants

Chemokine CXCR4 receptor modulators and uses related thereto

Grant US12582645B2 Kind: B2 Mar 24, 2026

Assignee

Emory University

Inventors

Dennis C. Liotta, Edgars Jecs, Robert James Wilson, Huy Hoang Nguyen, Michelle Bora Kim, Lawrence Wilson, Eric Miller, Yesim Altas Tahirovic, Valarie Truax

Abstract

The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. The receptor modulators can be formulated to form pharmaceutical compositions comprising the disclosed compounds or pharmaceutically acceptable salts or prodrugs thereof. The compositions may be used for managing CXCR4 related conditions, typically prevention or treatment of viral infections abnormal cellular proliferation, retinal degeneration, inflammatory diseases, or as an immunostimulant or immunosuppressant or for managing cancer and may be administered with another active ingredient such as an antiviral agent or chemotherapeutic agent.

CPC Classifications

C07D 401/12 C07D 401/14 C07D 405/14 C07D 413/14 C07D 417/12 C07D 417/14 C07D 471/04 C07D 487/04 C07D 487/08 A61P 35/00 A61K 31/4725 A61K 31/496 A61K 31/4985 A61K 31/4995 A61K 31/5377 A61K 31/541